Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21954984 | 0.77 | KDM4E (0.35) | NSD2CASP6L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3485848 | 0.74 | L3MBTL1 (0.45) | NSD2CASP6L3MBTL1ALDH1A1GAA | |
| SCHEMBL16631736 | 0.74 | NSD2 (0.39) | NSD2CASP6L3MBTL1ALDH1A1GAA | |
| SCHEMBL12621290 | 0.74 | HPGD (0.33) | L3MBTL1ALDH1A1HPGD | |
| SCHEMBL27256322 | 0.74 | CAPN1 (0.33) | L3MBTL1ALDH1A1SMN1; SMN2HPGDLMNA | |
| SCHEMBL23042886 | 0.71 | PKM (0.35) | L3MBTL1ALDH1A1GAAKDM4EHPGD | |
| SCHEMBL8507580 | 0.71 | PDE3B (0.36) | NSD2CASP6ALDH1A1POLBKDM4E | |
| SCHEMBL10926121 | 0.70 | NSD2 (0.41) | NSD2CASP6L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13007576 | 0.69 | SMN1; SMN2 (0.40) | NSD2CASP6L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18081737 | 0.69 | NSD2 (0.36) | NSD2CASP6L3MBTL1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105859643-A | Synthetic method of 2-ethyl-3,5,6-trimethyl pyrazine | 平光制药股份有限公司 | 2016-08-17 | — | — | CN | claimed |
| CN-118844594-A | Sweetener and flavor compositions, methods of making and methods of using the same | 伊比西(北京)植物药物技术有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-12048316-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2024-07-30 | — | — | US | disclosed |
| US-12029228-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC Natural Products Co., Ltd (CN) | 2024-07-09 | — | — | US | disclosed |
| US-11985994-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC Natural Products Co., Ltd (CN) | 2024-05-21 | — | — | US | disclosed |
| US-11849742-B2 | Tasteful natural sweetener and flavor | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2023-12-26 | — | — | US | disclosed |
| US-11793218-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC NATURAL PRODUCTS CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-11751593-B2 | Sweetener and flavor compositions, methods of making and methods of use thereof | EPC Natural Products Co., Ltd (CN) | 2023-09-12 | — | — | US | disclosed |
| CN-112218542-B | Sweetener and flavor compositions, methods of making and methods of using the same | 伊比西(北京)植物药物技术有限公司 | 2023-08-25 | — | — | CN | disclosed |
| EP-4223146-A1 | SWEETENER AND FLAVOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE THEREOF | EPC Natural Products Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20120328561-A1 | METHOD FOR TREATMENT OF INFLAMMATORY GASTROINTESTINAL DISORDERS | NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES (JP) | 2012-12-27 | — | — | US | disclosed |
| US-20100234385-A1 | Compsition Containing Biopterin and Method for Using The Same | KANEKA CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2123266-A1 | CANCER THERAPEUTIC AGENT AND ANTI-CARCINOGENIC AGENT | Kaneka Corporation (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090246186-A1 | AGENT FOR IMPROVING NERVOUS SYSTEM CELL FUNCTIONS | KANEKA CORPORATION (JP) | 2009-10-01 | — | — | US | disclosed |
| EP-2087887-A1 | HIGHLY ABSORBABLE COMPOSITION FOR ORAL ADMINISTRATION CONTAINING OXIDIZED COENZYME Q10 | Kaneka Corporation (JP) | 2009-08-12 | — | — | EP | disclosed |
| EP-2005951-A9 | AGENT FOR IMPROVING NERVOUS SYSTEM CELL FUNCTIONS | Kaneka Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| EP-2005951-A2 | AGENT FOR IMPROVING NERVOUS SYSTEM CELL FUNCTIONS | Kaneka Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-20080145411-A1 | COMPOSITION OF HIGH ABSORBABILITY FOR ORAL ADMINISTRATION COMPRISING OXIDIZED COENZYME Q10 | KANEKA CORPORATION (JP) | 2008-06-19 | — | — | US | disclosed |
| US-20080138326-A1 | Method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions of anticancer agents | KANEKA CORPORATION (JP) | 2008-06-12 | — | — | US | disclosed |
| US-5962662-A | Method for producing a flavorful and aromatic composition for use in smoking articles | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080138326-A1 | Method for cancer treatment, carcinogenesis suppression or mitigation of adverse reactions of anticancer agents | NQO1, SLC19A1, NDUFA6 | NSD2 1570/4885CASP6 819/4885L3MBTL1 3168/4885 |
| US-20080145411-A1 | COMPOSITION OF HIGH ABSORBABILITY FOR ORAL ADMINISTRATION COMPRISING OXIDIZED COENZYME Q10 | PLIN5, SLC25A20, PLIN3 | NSD2 1597/4885CASP6 2555/4885L3MBTL1 2721/4885 |
| US-20090246186-A1 | AGENT FOR IMPROVING NERVOUS SYSTEM CELL FUNCTIONS | NLN, BDNF, ACHE | NSD2 3843/4885CASP6 697/4885L3MBTL1 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.